The Rik of Endophthalmiti Following Intravitreal Triamcinolone Injection in the DRCRnet and CORE Clinical Trial

Purpoe To report the incidence of endophthalmiti following intravitreal injection uing a tandardized injection procedure. Deign Two randomized clinical trial. Method Nonpreerved intravitreal triamcinolone acetonide in prefilled yringe (Allergan, Inc, Irvine, California, UA) wa injected intravitreally in the Diabetic Retinopathy Clinical Reearch Network (DRCR net) and the tandard Care v COrticoteroid for REtinal Vein Occluion (CORE) clinical trial. The tandardized injection procedure did not include the ue of topical antibiotic during the day prior to the injection. Reult A of December 31, 2006, 1,378 intravitreal injection (538 eye) have been adminitered in the Diabetic Retinopathy Clinical Reearch Network Diabetic Macular Edema trial and 631 injection (301 eye) in tandard Care v COrticoteroid for REtinal Vein Occluion. There wa one cae of endophthalmiti in the 2,009 injection to date (0.05%, 95% confidence interval 0.001% to 0.277%). Concluion A low rate of endophthalmiti i achievable uing a tandardized procedure for intravitreal injection without precribing antibiotic prophylaxi on the day prior to the injection.